The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Deferasirox
Deferasirox · DEFERASIROX 360 mg/1 · Tablet · Oral · Msn Laboratories Private Limited
NDC 69539-0075-30 · 30 TABLET in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.2%chance of a new FDA shortage posting for deferasirox (oral solid) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market · price up 6% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,511.83 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA210945
- TE code
- AB
- Approval date
- Nov 20, 2019
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Deferasirox (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| AvKARE | DEFERASIROX 360 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Inc | DEFERASIROX 360 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Inc | DEFERASIROX 180 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Inc | DEFERASIROX 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Msn Laboratories Private Limited | DEFERASIROX 360 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Msn Laboratories Private Limited | DEFERASIROX 180 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Msn Laboratories Private Limited | DEFERASIROX 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Xiromed, LLC | DEFERASIROX 180 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Xiromed, LLC | DEFERASIROX 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Xiromed, LLC | DEFERASIROX 360 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Deferasirox — NDC 69539-0075-30," retrieved September 3, 2026, https://drugdashboards.com/drug/69539007530.
Free to cite with attribution — see how the data is put together.